Biosimilar insulins: current and future perspectives

Article Authors: Andrew J Krentz, Marcus Hompesch

no alt text set

Abstract

Biological products, also known as biologics, may be defined as biopharmaceutical products derived from living entities, that is, human, animal or microorganism sources. Recombinant protein drugs produced by cell culture fermentation technology have become a cornerstone of medical and especially endocrine practice over the last 25 years. Within this biopharmaceutical landscape, biosimilar medical products – also known as follow-on biologics – are intended to be clinically equivalent to an existing licensed biologic product.

no